Boston Scientific Highlights Key Therapies at Heart Rhythm 2026
Boston Scientific presented positive data for its FARAPULSE™ Pulsed Field Ablation and WATCHMAN™ Left Atrial Appendage Closure technologies at the Heart Rhythm 2026 conference, showcasing their safety and effectiveness based on late-breaking clinical trial results.
Positive data for FARAPULSE™ Pulsed Field Ablation and WATCHMAN™ LAAC Devices underscore therapy safety and effectiveness in late-breaking clinical trial sessions
MARLBOROUGH, Mass. and CHICAGO, April 26, 2026 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced data supporting use of the company’s FARAPULSE™ Pulsed Field Ablation (PFA) Platform and WATCHMAN™ Left Atrial Appendage Closure (LAAC) technologies. All data were presented at Heart Rhythm 2026, the annual meeting of the Heart Rhythm Society, held in Chicago from April 24-26.